Evidence map›Paper›PMID 29928423›Full record

ArticleOncology letters2018

Expression and clinical significance of miR-23a and MTSS1 in diffuse large B-cell lymphoma.

Mengwei Xu, Tao Xu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. MTSS1: beyond the integration of actin and membrane dynamics.Cellular and molecular life sciences : CMLS · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mengwei XuDepartment of Pathology, Xijing Hospital, Xi'an, Shanxi 710000, P.R. China.
Tao XuDepartment of Pathology, Xijing Hospital, Xi'an, Shanxi 710000, P.R. China.
Xijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study investigated the expression and clinical significance of micro-ribonucleic acid-23a (miR-23a) and metastasis suppressor 1 (MTSS1) in diffuse large B-cell lymphoma (DLBCL). A total of 70 cases of tumor tissues of patients with DLBCL and 30 cases of reactive lymphoid hyperplasia tissues were collected. OCI-LY10 cell was transfected with miR-23a antisense oligonucleotide (miR-23a ASO). The expression of miR-23a and MTSS1 in tumor tissues of patients with DLBCL and reactive lymphoid hyperplasia tissues were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry. Spearmans test was used for correlation analysis was also performed for their expression. The relationship of the expressions of miR-23a and MTSS1 with the pathological parameters of patients with DLBCL was further analyzed. The DLBCL OCI-LY10 cells were cultured

Indexed as

diffuse large B-cell lymphomametastasis suppressor 1micro-ribonucleic acid-23a

Identifiers

PMID29928423
PMCPMC6006423
OpenAlexW2800384970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.